Department of Allergy, Clínica Universidad de Navarra, Pamplona, Spain; RETIC de Asma, Reacciones adversas y Alérgicas (ARADYAL), Madrid, Spain.
Department of Preventive Medicine and Public Health, University of Navarra, IdisNA, Pamplona, Spain; CIBER de Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Instituto de Salud Carlos III, Madrid, Spain.
J Allergy Clin Immunol Pract. 2019 Nov-Dec;7(8):2714-2721. doi: 10.1016/j.jaip.2019.05.017. Epub 2019 May 24.
Suspicion of allergic drug reaction can cause important disturbances in the patient's life.
We evaluated in a prospective multicenter study the quality of life of patients who suffered a possible allergic drug reaction, and analyzed the effect of a drug allergy evaluation.
Patients (>18 years old) answered the specific questionnaire twice: before the drug allergy evaluation, and 1 month after it was completed. Statistics were performed using STATA.
A total of 360 patients (240, 66.6% female; mean age, 45.4 years; standard deviation [SD], 15.6 years) completed the first questionnaire. After the evaluation, 150 of 346 patients (43.4%) were diagnosed as allergic to the drug (115 of 150 immediate; 35 of 150 delayed) and 196 of 346 patients (56.6%) as nonallergic. The mean value of the first questionnaire was 32.14 (SD, 11.84); patients with anaphylaxis, nonanaphylactic immediate reaction, with more than 1 drug reaction, or a chronic osteoarticular disease, had a statistically significant higher score in Q0 (worse quality of life). After the allergy study, the mean of the second questionnaire was 27.27 (SD, 9.96), showing a global improvement (P < .001). No statistically significant difference was found between drug allergic and non-drug allergic patients (P = .340); however, being >40 years old (P = .030), having a chronic osteoarticular disease (P = .003) and having more than 1 reaction to drugs (P < .001) were associated with a statistically significant worse quality of life after the evaluation.
Having suffered anaphylaxis, more than 1 reported drug allergy or presenting a musculoskeletal disease are factors that worsen the quality of life. Quality of life improved significantly after completing a drug allergy evaluation.
对药物过敏反应的怀疑可能会给患者的生活带来重大干扰。
我们在一项前瞻性多中心研究中评估了发生疑似药物过敏反应的患者的生活质量,并分析了药物过敏评估的效果。
患者(>18 岁)两次回答特定问卷:在药物过敏评估之前和完成后 1 个月。使用 STATA 进行统计学分析。
共有 360 例患者(240 例,66.6%为女性;平均年龄为 45.4 岁;标准差[SD]为 15.6 岁)完成了第一个问卷。评估后,346 例患者中有 150 例(43.4%)被诊断为药物过敏(150 例中 115 例为即刻过敏,35 例为迟发型过敏),346 例患者中有 196 例(56.6%)为非过敏。第一个问卷的平均值为 32.14(SD,11.84);发生过敏反应的患者、非过敏即刻反应的患者、有 1 种以上药物反应的患者或患有慢性骨关节炎的患者,在 Q0 方面(生活质量更差)的评分具有统计学意义上的更高得分。过敏研究后,第二个问卷的平均值为 27.27(SD,9.96),显示出整体改善(P<0.001)。药物过敏和非药物过敏患者之间无统计学显著差异(P=0.340);然而,年龄>40 岁(P=0.030)、患有慢性骨关节炎(P=0.003)和有 1 种以上药物反应(P<0.001)与评估后生活质量的统计学显著恶化相关。
发生过敏反应、有 1 种以上报告的药物过敏或患有肌肉骨骼疾病是生活质量恶化的因素。完成药物过敏评估后,生活质量显著改善。